Testagen Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Testagen dosing — protocols, safety, and where to buy.
Dose Range
10 mg oral capsule, 1-2 daily for 10-30 days
Dosage Calculator
Calculate exact dosing for Testagen.
Dosing Protocols
A beginner approach to Testagen is conservative and assumes the user has not yet done a serious workup for male hormonal or fertility concerns. Before starting, complete a morning lab draw including total testosterone, free testosterone (or SHBG-calculated), estradiol (sensitive assay), LH, FSH, prolactin, TSH, fasting glucose and insulin, CBC, CMP, PSA (if age 45+ or earlier with family history), and vitamin D. Do the draw between 7 and 10 AM on a fasted, rested morning. Repeat abnormal values on a second morning at least one week later before concluding anything is truly abnormal.
If lab values are normal and the user is under 40 with no specific fertility or hormonal concern, Testagen is not recommended as a first intervention. Sleep, resistance training, nutrition, stress management, and body composition optimization have far larger effects on male hormonal and reproductive health at that age than any peptide bioregulator.
If the user has confirmed subclinical low testosterone (total testosterone 300 to 450 ng/dL range with symptoms) and has declined or not yet pursued formal TRT, a Testagen cycle is reasonable as an experimental step. Beginner cycle: 1 capsule (20 mg nominal, approximately 2 to 4 mg peptide) on an empty stomach each morning for 10 consecutive days. Wait 60 to 90 days without peptide use. Then optionally repeat. Limit to two cycles per year in the first year.
During the cycle the user should keep a simple log: morning energy (1 to 10), libido (1 to 10), mood (1 to 10), sleep quality (1 to 10), workout performance (1 to 10). Record daily for the 10-day cycle and for 30 days after. This provides a structured self-experiment with baseline and post-cycle data. Without a log, post-hoc perception tends to exaggerate both positive and negative responses.
Retest labs 30 to 45 days after the cycle ends. Compare total testosterone, free testosterone, estradiol, LH, and FSH to baseline. A meaningful biochemical response would be a 15 to 30 percent rise in total testosterone. A change smaller than 10 percent is within analytical noise for many labs. A change larger than 50 percent is unlikely from Testagen alone and warrants investigation of confounders (new supplement, lifestyle change, lab variability).
Beginner users should not combine Testagen with TRT, clomiphene, enclomiphene, hCG, SARMs, or anabolic steroids in the first cycle. Running Testagen as a solo experiment allows the user to attribute any observed change to the peptide (with appropriate uncertainty about placebo). Layering is a later-cycle consideration.
Do not use Testagen while actively trying to conceive without consulting a reproductive urologist. The effects on spermatogenesis are not well characterized, and introducing an unknown variable into a fertility timeline is not advised.
Do not use Testagen in the presence of active prostate cancer, elevated PSA under investigation, or diagnosed breast cancer in a male. These are absolute contraindications.
Stop the cycle immediately and seek medical attention if any of the following occur: severe headache, new chest pain, new shortness of breath, severe allergic symptoms (hives, swelling of lips or tongue, difficulty breathing), pelvic or testicular pain, or gross hematuria. These are not expected effects of Testagen but should trigger evaluation if they do occur.
An intermediate approach assumes the user has completed at least one conservative Testagen cycle, has baseline and post-cycle labs, has tolerated the peptide, and wants to extend the experiment with layered optimization. This approach is appropriate for a man in his forties or fifties with confirmed subclinical or mild hypogonadism who has declined formal TRT, has optimized lifestyle factors, and is working with a clinician willing to order labs and interpret results.
Intermediate cycle: 2 capsules (40 mg nominal, approximately 4 to 8 mg peptide) daily, split morning and early afternoon on an empty stomach, for 10 consecutive days. Wait 60 to 90 days. Repeat up to three times per year.
Within the 10-day cycle, the user may layer additional short peptides from the Khavinson family if the goal is broad axis support. A common intermediate rotation pairs Testagen with a single additional peptide per cycle — Thymogen (immune), Pinealon (neurological), or Epitalon (pineal/sleep/circadian). Running two Khavinson peptides simultaneously is experimental and not supported by trial evidence, but it is the common practice among users pursuing bioregulator stacking.
Between cycles, the intermediate user maintains an evidence-graded baseline stack. That baseline includes: vitamin D dosed to reach 40 to 60 ng/mL serum (typically 2000 to 5000 IU daily), zinc 25 to 30 mg daily, magnesium glycinate 300 to 400 mg at bedtime, omega-3 EPA+DHA 1 to 2 g daily, creatine monohydrate 5 g daily, and a multi-B complex. These have broader evidence bases than any bioregulator and support the HPG axis through general nutritional sufficiency.
For users pursuing fertility goals in addition to hormonal support, the intermediate stack adds CoQ10 200 to 400 mg daily, L-carnitine 1 to 3 g daily, folate 800 mcg daily, and selenium 200 mcg daily. These should be run continuously for at least three months before a new semen analysis is meaningful (because spermatogenesis is a 74-day cycle).
Monitoring during an intermediate phase: labs every six months with total testosterone, free testosterone, estradiol, LH, FSH, SHBG, PSA (from age 45), CBC, and CMP. Semen analysis annually if fertility is the concern. Blood pressure and resting heart rate at home monthly. Weight, waist circumference, and body composition quarterly.
The intermediate user should develop a clearer sense of whether Testagen is generating a reproducible benefit. After three cycles with documented labs and symptom logs, if there is no detectable biochemical response and no consistent symptomatic benefit, the honest conclusion is that Testagen is not working for this user. Continuing beyond that point is opportunity cost — time and money that would be better spent on a formal urology consultation, TRT, clomiphene, or further lifestyle optimization.
If the user is producing a detectable biochemical response (15 to 30 percent testosterone rise, mild estradiol rise, stable LH) and a subjective benefit, the intermediate approach is to continue biannual or triannual cycling with ongoing monitoring. Do not chase larger responses by increasing dose beyond 2 capsules daily. Dose-response data above that point are absent.
Intermediate users should specifically watch for PSA drift. Baseline PSA followed by repeat PSA 6 months later is reasonable. Any rise above 1.0 ng/mL in a year, or any absolute value above 4.0 ng/mL (or above age-adjusted thresholds), warrants urology referral and pause of Testagen cycling pending evaluation.
An advanced approach is appropriate only for users who have multiple documented cycles behind them, stable labs, a working clinician relationship, and a clear goal for what they are trying to achieve. Most men should not run an advanced Testagen protocol. The incremental benefit over an intermediate approach is small, and the complexity of monitoring and interpretation rises sharply.
Advanced cycle: 2 to 3 capsules daily (40 to 60 mg nominal, approximately 4 to 12 mg peptide), split across morning and afternoon, for 10 consecutive days. Wait 60 to 90 days. Up to four cycles per year.
Advanced users sometimes layer a Khavinson bioregulator stack of three or four peptides across a single cycle, rotating the lead peptide each cycle. For example: Cycle 1 lead Epitalon with background Testagen and Thymogen. Cycle 2 lead Testagen with background Pinealon and Vesugen. Cycle 3 lead Thymogen with background Livagen and Vilon. This is a self-experimental framework without randomized trial evidence. Users pursuing this should acknowledge they are generating n=1 data, not following a validated protocol.
At the advanced level, the user should consider whether the Testagen experiment is generating enough benefit to justify continuing. Realistic thresholds: a reproducible 20 to 30 percent testosterone rise on lab, a consistent symptomatic improvement (libido, energy, mood) that survives blinded self-assessment (scoring symptoms on random days without knowing whether you are in an active cycle), and no adverse safety signals on PSA, CBC, or CMP. If any of these thresholds is missed, the honest advanced move is to stop cycling and reconsider formal pharmacological intervention (TRT, clomiphene, enclomiphene, or hCG) that has a much stronger evidence base.
Advanced users pairing Testagen with TRT should understand that the interaction is poorly characterized. TRT suppresses endogenous LH, which theoretically limits any downstream effect of a peripheral Leydig-cell support peptide. Adding Testagen to a stable TRT regimen is unlikely to change serum testosterone meaningfully. Some users do it anyway on the theory that it supports testicular tissue health during suppression — the same theory that underlies adjunct low-dose hCG (250 IU three times weekly), which has vastly better evidence for that specific role.
Advanced users pairing Testagen with clomiphene or enclomiphene should be aware of the theoretical redundancy. Both aim to raise endogenous testosterone. Running them together is unlikely to produce additive benefit beyond what the SERM alone delivers, and may obscure interpretation of what is driving observed changes.
Advanced users pairing Testagen with hCG should be aware of the similar redundancy. hCG directly stimulates Leydig cells through LH receptors. Testagen claims to support the same cell type through a different pathway. Running both is unlikely to produce additive benefit beyond hCG alone.
Monitoring at the advanced level: labs every three to four months with total testosterone, free testosterone, estradiol, LH, FSH, SHBG, DHEA-S, cortisol (morning), PSA, CBC, CMP, fasting glucose and insulin, HbA1c, lipid panel, hs-CRP, and vitamin D. Semen analysis every six to twelve months if fertility is a goal. Imaging (scrotal ultrasound, DRE) annually from age 50 or on indication.
Advanced users should maintain a clinical partnership. A urologist, endocrinologist, or men's health specialist who is willing to review labs and discuss the bioregulator context is necessary for safe long-term use. Self-managed long-term cycling without clinician oversight is not recommended.
At any advanced stage, the most important question to revisit is whether the evidence-based alternatives have been fully exercised. A reader pursuing multi-year Testagen cycling who has never tried a three-month enclomiphene trial, never had a proper varicocele workup, never optimized body composition to a waist under 40 inches, or never trained a structured resistance program is making a choice to chase a weaker intervention in place of stronger ones. The advanced protocol on this page is written to support informed self-experimentation, not to imply that Testagen is a sufficient answer for any serious male hormonal or fertility concern. The strongest answer remains: urology workup, evidence-based pharmacology, and lifestyle — and then, optionally, Testagen as an adjunct.
Commonly Stacked With
Testagen stacking decisions depend entirely on the user's goal. This section describes realistic combinations for three common goals — age-related low-T symptoms, subfertility, and generalized "male longevity" — with explicit emphasis that higher-evidence options exist for each.
For age-related low-T symptoms (fatigue, libido decline, erectile softening, mood flattening in men over 40) the most evidence-based stack is not built around Testagen. It is built around a lab-confirmed diagnosis and a Western pharmaceutical response. That looks like: total testosterone, free testosterone, SHBG, LH, FSH, estradiol (sensitive assay), prolactin, TSH, and a morning cortisol on two separate mornings at least a week apart. If total testosterone is below 300 ng/dL on two confirmed draws and the man has symptoms, treatment is standard. First-line is either testosterone cypionate 80 to 200 mg per week (split into twice-weekly injections), daily transdermal testosterone, or intranasal testosterone. For men who want to preserve fertility, enclomiphene 12.5 mg daily or every other day, or clomiphene 25 mg every other day, raises endogenous testosterone while preserving spermatogenesis. hCG 500 to 1500 IU twice weekly is an alternative. These pharmacological options have orders of magnitude more evidence than Testagen.
In that standard workup, where could Testagen fit? Realistically, three niches. First, a man with symptoms and a total testosterone in the 300 to 400 ng/dL range — the classical "gray zone" where guideline-based TRT is discouraged — who has already corrected lifestyle factors and wants to try something mild before committing to pharmacological therapy. Second, a man who has decided against TRT for personal reasons (doesn't want injections, doesn't want long-term medication, concerns about fertility suppression) and wants a less-evidenced but less-committing option. Third, a man already on stable TRT who wants to experiment with layered bioregulator support for general vitality, not as a primary effect. In all three niches the reasonable expectation is modest effect, not transformation.
For subfertility the standard workup is semen analysis (two samples over at least a month apart), FSH, LH, total and free testosterone, SHBG, estradiol, prolactin, TSH, genetic testing if sperm count is very low (Y-chromosome microdeletions, karyotype), scrotal ultrasound for varicocele, and a reproductive urology consultation. Evidence-based treatments include varicocelectomy for clinically significant varicocele (meta-analyses support improved sperm parameters and pregnancy rates), clomiphene or enclomiphene for secondary hypogonadism with preserved response, hCG for isolated hypogonadotropic hypogonadism, and recombinant FSH in selected cases. Micronutrient optimization — CoQ10 200 to 400 mg daily, L-carnitine 1 to 3 g daily, zinc 25 to 50 mg daily, selenium 200 mcg daily, folate 800 mcg daily, vitamin D sufficient to reach 30 to 60 ng/mL serum — has the strongest Cochrane-level support for improving sperm parameters.
Where would Testagen fit in a fertility stack? At most as a low-priority adjunct, added after all the above have been optimized for at least three to six months. The cycle length (10 days) and washout (60 to 90 days) means Testagen contributes to at most two or three short windows per year, which is not a strong therapeutic dose-schedule for a fertility goal that typically requires months of continuous axis support. A man actively trying to conceive should prioritize the Cochrane-supported interventions and treat Testagen as experimental.
For generalized "male longevity" the realistic stack is: resistance training three to four times a week, zone 2 cardio two to three times a week, VO2max work once a week, sleep seven to nine hours, Mediterranean-style diet, waist circumference below 40 inches (102 cm), blood pressure below 130/80, LDL-C appropriate for cardiovascular risk (often below 70 mg/dL with statin in established disease), HbA1c below 5.7 percent, annual PSA from age 45 or 50 depending on risk, colonoscopy at 45, skin checks, and evidence-based pharmacology where risk factors warrant (metformin in prediabetes; statin in appropriate lipid or risk contexts; TRT if diagnosed). That stack is not Testagen-centric. It is Western preventive medicine.
Within that framework, Testagen can plug in as part of a Khavinson bioregulator rotation for the user who wants to experiment with the peptide line. A common rotation layers Epitalon (pineal/telomere), Thymogen (immune), Pinealon (neurological), and Testagen (male reproductive), one at a time, with washouts. Some users rotate through four to six bioregulators per year. That is a self-experiment protocol, not a medical regimen.
Combining Testagen with TRT: theoretically compatible. TRT suppresses endogenous LH and testosterone production; adding a peripheral Leydig-cell support peptide does not undo that suppression (because there is little endogenous LH signal to amplify), so Testagen is unlikely to contribute much on top of TRT. Some men add it anyway on the theory that it supports general testicular tissue health during TRT, similar to how some add low-dose hCG (250 IU three times weekly) for the same purpose. hCG has vastly better evidence for this specific role than Testagen does.
Combining Testagen with clomiphene or enclomiphene: theoretically redundant. Both agents aim to raise endogenous testosterone. Clomiphene or enclomiphene does so by central HPG stimulation (with strong evidence). Testagen claims to do so by peripheral Leydig-cell support (with weak evidence). Running both is unlikely to produce additive benefit beyond what clomiphene or enclomiphene alone delivers.
Combining Testagen with hCG: theoretically redundant. hCG directly stimulates Leydig cells through LH receptors. Testagen claims to support Leydig-cell steroidogenesis through a different mechanism. Running both is unlikely to produce additive benefit beyond what hCG alone delivers.
Combining Testagen with a SARM (like ostarine) or an anabolic-androgenic steroid: not recommended. SARMs and AAS carry their own risk profiles and create hormonal situations (HPG suppression, altered lipid panels, liver stress) that make layering a bioregulator both low-signal and potentially confusing for the user trying to interpret side effects.
Cross-family stacking: Testagen pairs conceptually with Prostamax (prostate bioregulator) for men over 50 who are treating both mild low-T and early BPH symptoms. It pairs with Vesugen for men whose concerns include vascular function and erectile quality. In a household context it mirrors Ovagen (female reproductive bioregulator) so partners pursuing parallel male-and-female self-experiments can run analogous 10-day cycles with matched washouts. Some users further layer Epitalon for circadian and telomere support, Pinealon for cognitive support, or Thymogen for immune support across the same annual calendar. None of these combinations has trial-level evidence. All are reasonable self-experiments within the Khavinson framework for users committed to that approach.
Side Effects & Safety
Contraindications
Absolute contraindications to Testagen include active prostate cancer, any elevated prostate-specific antigen (PSA) under investigation (for example a PSA above 4.0 ng/mL without a current biopsy-confirmed benign explanation), a personal history of breast cancer in a male, known hypersensitivity to short-peptide bioregulators or to the capsule excipients (milk-protein isolates, starch), and pregnancy or breastfeeding (for any female partner considering use — the compound is intended for male use, but the general principle of avoiding bioregulator peptides in pregnancy applies to any household in which capsules are present and potentially accessible). Any of these is a reason not to start Testagen. Relative contraindications — reasons to defer Testagen until the issue is clarified — include: PSA in the gray zone (2.5 to 4.0 ng/mL) without recent urology evaluation; high-normal baseline hematocrit (above 52 percent); untreated obstructive sleep apnea with significant symptoms; untreated severe hypertension (resting blood pressure above 160/100); active azoospermia being worked up for obstructive versus non-obstructive etiology; active clomiphene, enclomiphene, or hCG therapy directed by a reproductive specialist for a specific fertility timeline; and any systemic condition under active diagnostic workup where introducing an uncharacterized variable would complicate interpretation. Age considerations: Testagen is intended for adult men. It is not intended for adolescents or adults under 25. The HPG axis in younger men is fundamentally different from that in older men — baseline testosterone is typically sufficient, LH and FSH feedback is intact, and the "age-related decline" that Testagen targets is not relevant. Younger men with hormonal symptoms should see a reproductive endocrinologist for workup, not self-administer a bioregulator developed for an older cohort. Cardiovascular disease: Testagen has no documented acute cardiovascular effect, but any intervention that even modestly raises testosterone and estradiol enters the cardiovascular conversation. The TRAVERSE trial showed that TRT in hypogonadal men with cardiovascular risk factors does not increase major adverse cardiovascular events over four years ([Lincoff et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37326322/)), but that trial was in men with clear indications for TRT and appropriate monitoring. Men with recent myocardial infarction, recent stroke, severe heart failure, or unstable arrhythmia should defer Testagen until stable and in consultation with cardiology. Thromboembolic disease: men with a history of deep venous thrombosis, pulmonary embolism, or known thrombophilia (factor V Leiden, prothrombin 20210A mutation, protein C or S deficiency) should be cautious with any intervention that raises testosterone, given the theoretical risk of worsened red-cell mass and the documented (if modest) association between TRT and thrombotic events in select populations. The effect of Testagen specifically on hematocrit and thrombotic risk is not documented; the prudent approach is to avoid it in this population. Liver disease: no documented hepatotoxicity signal from Testagen, but any new compound in a patient with cirrhosis or significant hepatic impairment warrants caution. Testagen is not metabolized by the liver in a manner that is pharmacokinetically characterized in the Western literature, so extrapolation is speculative. In advanced liver disease, defer. Kidney disease: similar caveat to liver. No documented nephrotoxicity signal from Testagen, but no renal dose adjustment data exist either. In advanced chronic kidney disease (eGFR below 30), defer in favor of interventions with better-characterized renal safety. Active infection: defer Testagen during acute systemic infection. The published data do not support any benefit during illness, and layering an uncharacterized variable during illness complicates interpretation of symptoms and lab changes. Drug interactions: - Testosterone replacement therapy: theoretically compatible but likely redundant; see Stacking Notes. - Clomiphene or enclomiphene: theoretically redundant; see Stacking Notes. - hCG: theoretically redundant; see Stacking Notes. - Finasteride or dutasteride: combined use reduces the conversion of any testosterone rise to dihydrotestosterone (DHT), which may blunt some downstream effects. No safety concern per se. - Anastrozole: combined use reduces the conversion of any testosterone rise to estradiol. No safety concern. - Selective serotonin reuptake inhibitors (SSRIs): some SSRIs suppress libido and erectile function; Testagen is unlikely to fully counteract this. No safety concern. - Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): no documented interaction; theoretical concern if hematocrit rises from testosterone response. - PDE5 inhibitors (tadalafil, sildenafil, vardenafil): no interaction. - 5-alpha-reductase inhibitors for hair loss: see finasteride above. Pregnancy: as noted, Testagen is not indicated for women. A male user's female partner who is pregnant or breastfeeding is not affected by Testagen cycling in the male, but capsules should be stored safely out of reach of children and non-users. Fertility timing: a man actively trying to conceive should consult a reproductive urologist before introducing any variable — Testagen or otherwise — into his HPG axis. The 74-day spermatogenesis cycle means any effect on sperm parameters requires 3 months of observation to assess. Operating machinery, driving: no documented effect on cognition or reaction time. Testagen is not expected to impair. Alcohol use: no direct interaction, but chronic heavy alcohol use suppresses testosterone and sperm parameters independently. A reader cycling Testagen while drinking heavily is working against their own goal. Cannabis use: chronic heavy cannabis use has been associated with modestly lower testosterone and impaired sperm parameters. Same logic applies. Anabolic steroid use: contraindication. Running Testagen alongside AAS does not make sense mechanistically (AAS suppresses endogenous LH and testosterone production, so peripheral Leydig support has little upstream signal to amplify) and it conflates interpretation of any perceived benefit. Long-term use beyond two years of repeated cycling: no published data. The prudent approach is to revisit the decision annually based on continued benefit, continued safety labs, and continued absence of alternatives with better evidence. A user who has been cycling Testagen for three years without a clear reproducible benefit should stop and redirect to evidence-based interventions.
Additional Notes
Commercial Testagen capsules marketed in Russia and Eastern European research markets contain 20 mg of total powder per capsule. Of that 20 mg, approximately 2 to 4 mg is the synthetic peptide active; the balance is a proprietary blend of milk-protein isolates, starch, and other excipients used across the Khavinson oral bioregulator line. Readers should understand that "20 mg capsule" does not mean a 20 mg peptide dose. The peptide dose per capsule is modest — comparable in quantity to sublingual or oral peptide formulations of similar class.
Standard oral dosing in Khavinson-group human observations has been 1 to 2 capsules daily for 10 consecutive days, cycled with a 60 to 90 day washout before any repeat cycle. Dose timing is typically morning, on an empty stomach, with water, about 15 to 30 minutes before food. If a second capsule is taken, it is usually given early afternoon on an empty stomach between meals.
There is no dose-ranging data to support advanced dosing schemes beyond 2 capsules per day. Users cycling 3 or 4 capsules daily are operating beyond the published observational data. Empirical reports on vendor forums suggest no consistent benefit to higher oral doses. The ceiling on effect at oral Testagen is likely determined by absorption and first-pass rather than by the dose administered.
Injectable Testagen is a research-chemical formulation rather than the commercial product. Users pursuing injectable dosing typically reconstitute lyophilized peptide with bacteriostatic water and administer 50 to 200 mcg subcutaneously daily during a 10 to 20 day cycle. Injectable protocols are much less studied than oral cycling and carry additional risks (sterile technique, injection site reactions, dose uncertainty from research-chemical quality variability). The conservative recommendation on this page is to use the oral capsule if any Testagen is used at all. Injectable Testagen is not recommended for any user without research-chemical experience and clinical oversight.
Cycling convention is 10-days-on / 60-to-90-days-off per the standard Khavinson framework. The rationale for that specific pattern is theoretical: Khavinson proposes that short-peptide bioregulators reset gene expression patterns during the active cycle and that the washout allows the reset effect to consolidate without continuous peptide presence. There is no direct evidence comparing 10-day cycles with 20-day cycles, 30-day cycles, or continuous daily dosing. The 10-day convention is therefore a tradition, not a validated pharmacokinetic recommendation.
The typical annual cadence is 2 to 4 cycles per year. Most Khavinson-group protocols do 2 cycles (spring and autumn). Users with specific goals may do 3 or 4 cycles if they tolerate well and are monitoring labs. Cycling more than 4 times a year is not supported by data and likely produces diminishing returns.
Dose for fertility goals versus dose for hormonal symptoms is not differentiated in the published data. The same cycle (1 to 2 capsules daily for 10 days) is used regardless of goal. For fertility specifically, the issue is that spermatogenesis takes approximately 74 days from stem cell to mature spermatid. A 10-day active window followed by 60 to 90 days of washout aligns only loosely with that biology. Users pursuing fertility goals should not expect a short cycle to translate into semen analysis changes measurable in the subsequent month; any changes, if present, would take three months to appear.
Dose for men on concurrent TRT, clomiphene, enclomiphene, or hCG: not established. Layering Testagen with existing hormonal pharmacology has no published dose guidance. Users doing this should maintain the standard 1 to 2 capsules daily for 10 days cycling and not try to adjust dose based on concurrent medications.
Storage: capsules should be kept in a cool dry place out of direct sunlight. Refrigeration is not required for sealed bottles but extends shelf life once opened. Shelf life is typically 24 months from manufacture for sealed bottles. Discard if color, odor, or appearance change.
Missed doses during a 10-day cycle: skip the missed dose and resume the next day. Do not double up. A cycle interrupted by more than 2 missed days is best terminated and restarted fresh after the standard washout.
Interaction with food: oral bioavailability is thought to be modestly better on an empty stomach, though quantitative data are limited. Taking with food does not eliminate absorption; it likely reduces peak concentration. The standard recommendation is empty stomach for reproducibility.
Interaction with alcohol: no direct interaction data. A cycle is short enough that abstaining from alcohol for 10 days is trivial. Chronic alcohol intake is an independent suppressor of testosterone and semen parameters; a reader cycling Testagen while drinking heavily is working against their own goal.
Dose for adults over 70: not specifically studied. The same 1 to 2 capsules daily is used. Elderly users should pay additional attention to PSA monitoring and to drug interactions with any prescription medications.
Dose for adolescents or adults under 25: not studied, not recommended. The HPG axis in younger men is not the target population for a geriatric-origin bioregulator framework. Younger men with hormonal concerns should see a reproductive endocrinologist, not self-administer Testagen.
Frequently Asked Questions
What is the recommended Testagen dosage?
The typical dose range for Testagen is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.
How often should I take Testagen?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Testagen need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Testagen side effects?
Side effects reported in the Khavinson-group Testagen literature are minimal. The published observational data from the Saint Petersburg Institute of Bioregulation and Gerontology consistently describe Testagen as well tolerated at the recommended oral dose (1 to 2 capsules daily for 10 days, repeated once or twice yearly). Specific adverse events noted in Russian clinical observations include occasional mild gastrointestinal discomfort, infrequent transient headache, and rare reports of skin flushing during the first few days of a cycle. Serious adverse events attributable to Testagen are not documented in the published literature. That is a reassuring safety profile on paper, but the reader should understand the limits of the data. Most Testagen studies are small (tens of patients, not hundreds or thousands), short in follow-up (weeks to a few months), and non-placebo-controlled. The minimum threshold to detect a rare serious adverse event — hepatotoxicity, prothrombotic effect, prostate tumor promotion, sperm DNA damage — is tens of thousands of patient-years of exposure, which Testagen has never accumulated in published form. "Well tolerated in small trials" is not the same as "safe for long-term unsupervised use." Theoretical concerns specific to Testagen, derived from its proposed mechanism of action on the male reproductive axis, deserve explicit discussion. Prostate tumor promotion is the single most important theoretical concern. Testagen is claimed to support Leydig-cell steroidogenesis and downstream androgen signaling. Any intervention that raises testosterone — whether directly (TRT), centrally (clomiphene, enclomiphene), or peripherally (hCG, Testagen if the claim holds) — carries a theoretical concern about androgen-sensitive tumor biology. This is why standard urology practice requires baseline PSA and digital rectal exam before starting TRT, and repeat PSA monitoring during therapy. The same standard of care should apply to any man starting Testagen, especially over age 50. A baseline PSA and DRE should be done before starting. Any PSA rise of more than 1.0 ng/mL in a year, or any PSA above 4.0 ng/mL, warrants urology referral before continuing. Estradiol elevation is a related concern. A rise in testosterone produces a proportional rise in estradiol via aromatase activity in adipose tissue, brain, and gonad. Men starting Testagen should be aware that symptoms of elevated estradiol — water retention, nipple tenderness, mood lability, libido changes — can emerge if the testosterone response is substantial. In conventional TRT practice, these symptoms trigger a reconsideration of dose or occasional use of anastrozole. In the much weaker Testagen setting, these symptoms are less likely to occur but should still be watched for. Erythrocytosis, a rise in hematocrit, is the third classical TRT side effect. It is unlikely to manifest from Testagen alone given the modest testosterone response expected, but a baseline CBC before starting and a follow-up CBC after one or two cycles is a reasonable check, especially in men who already have baseline high-normal hematocrit. Sleep apnea worsening is a fourth TRT-associated concern. In men with undiagnosed or untreated obstructive sleep apnea, any rise in testosterone can theoretically worsen the condition. A man starting Testagen who snores heavily, has witnessed apneic episodes, or has daytime hypersomnolence should have a sleep study before assuming symptoms are from hormones. Fertility considerations cut in both directions. A man hoping to conceive should be cautious with any intervention that changes the HPG axis. TRT, for example, reliably suppresses spermatogenesis through negative feedback at the hypothalamus. Testagen, if it acts primarily at the Leydig cell without central feedback, theoretically avoids that problem. If it acts centrally through GnRH, it could in principle either support or suppress spermatogenesis depending on the net effect on pituitary FSH. The published human data are not detailed enough to resolve this. A man actively trying to conceive should work with a reproductive urologist and avoid introducing a variable with poorly characterized effects on the axis. Allergic reactions to peptide therapeutics are rare but possible. Hives, itching, lip or tongue swelling, or breathing difficulty after a dose warrant immediate cessation and medical attention. The oral capsule formulation includes milk-protein and starch excipients, which matter for patients with lactose intolerance or milk allergy. Drug interaction data for Testagen are effectively non-existent in the Western literature. Theoretical interactions of concern include: combined use with TRT (could stack androgen effects), combined use with clomiphene or enclomiphene (could stack central HPG stimulation), combined use with 5-alpha-reductase inhibitors like finasteride or dutasteride (unclear net effect on androgen signaling), and combined use with anticoagulants (no evidence of interaction, but not studied). Long-term safety data beyond one year of repeated cycling do not exist in published form. The Khavinson framework recommends cycling as a safety feature — 10 days on, 60 to 90 days off — but the rationale for that specific cycle length is theoretical rather than empirical. A reader using Testagen for multiple years should recognize they are operating beyond the evidence base and should monitor testosterone, estradiol, PSA, and hematocrit annually at minimum. Finally, the most common real-world "side effect" of Testagen use is opportunity cost. A man who buys Testagen, does a cycle, notices modest or no change, and concludes "peptides don't work for me" has often bypassed the interventions with the strongest evidence — a real urology workup, lifestyle correction, and pharmacologically proven therapy. Framed that way, the worst side effect of Testagen is that it can delay effective treatment. This is the honest conversion-optimized framing: Testagen is not dangerous in the typical dose range, but it is frequently the wrong choice, and the right choice is a reproductive urologist or men's health specialist.
Where can I buy Testagen?
Visit our vendor directory to find trusted sources for Testagen.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.